Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.
This search will output a list of trials for which you may be eligible based on the criteria you enter.
For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.
|NCT04239014||II||Recurrent platinum sensitive ovarian cancer with PARP inhibitor maintenance therapy following last platinum-based therapy||A Phase 2 Randomized, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients With Platinum Sensitive Relapsed Epithelial Ovarian Cancer, Who Have Previously Received PARP Inhibitor Maintenance Treatment||AK, CA, CT, FL, GA, KY, LA, MI, MN, NJ, NY, OH, OK, OR, PA, RI, SC, SD, TX, VA, WA||View Drugs||View Results |
|Ceralasertib||AZD6738, ATR kinase inhibitor AZD6738||ATR kinase inhibitor||Clinical Trials|
|Olaparib||AZD2281, Lynparza||PARP inhibitor||Approved in Ovarian Cancer|
|NCT04377087||II||Platinum sensitive ovarian cancer with response to most recent Pt-based therapy (maintenance)||Phase IIA Trial of Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer||PA||View Drugs|
|NCT02737787||I||Recurrent ovarian cancer with CR in second or greater remission||A Phase I Study of Concomitant WT1 Analog Peptide Vaccine or NY-ESO-1 Overlapping Peptides Vaccine in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission||NJ, NY||View Drugs||View Results |
|Galinpepimut-S||SLS 001, WT-1 analog peptide vaccine SLS-001||Immune response against cancer expressing WT1||Clinical Trials|
|Nivolumab||BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo||Blocks PD-L1/2 inhibition of T cells||Approved in Other Cancers|
|NY-ESO1 vaccine||Immune response against cancer expressing NY-ESO-1||Clinical Trials|